NorwayNorway

Norway: Biobank assets to be privatised?

06.03.2010

Oslo/Levanger – A report released by the Research Council of Norway (RCN) proposes setting up a national biobank company in Norway. After analysing ethical, judicial and political arguments, the study ordered by the Norwegian Ministry of Education and Research and the Ministry of Health and Care Services suggests a single company should commercialise biomaterials assets from the country’s resources. Since 1943, Norwegian hospitals, research institutions, and governmental health authorities have collected and systemised large amounts of biological material and patient data. This has given rise over the years to almost 2,000 research-based biobanks and close to 200 clinical biobanks. The report recommends using Hunt Biosciences as a model for a national company.
Hunt Biosciences was established in 2007 to provide pharma companies with bio­marker discovery and validation services using biosamples collected over a quarter of a century from more than 250,000 people in the Nord-Trøndelag region. The company, which is owned by the Norwegian University of Science and Technology (NTNU) and North Trøndelag county, holds an exclusive commercial license to the NTNU-biobank material. The proposed biobank company could obtain a similar license for all Norwegian material.

NorwayNorway

05.04.2011

Oslo – Norwegian Algeta ASA has entered a research collaboration with Genzyme to evaluate the potential of its Thorium platform Under the terms of the agreement, Genzyme will provide access to a novel tumour-targeting antibody,...

NorwayNorway

05.04.2011

Trondheim – Norway-based APIM Therapeutics AS has received a follow-up investment from Sarsia Seed, one of its previous investors. APIM focusses on novel drug candidates that potentiate the action of current chemo­therapeutics to...

NorwayNorway

04.11.2010

Oslo – Norwegian diagnostic specialist DiaGenic ASA has raised NOK70m (EUR 8.5m) through the sale of 140 million shares at NOK0.50 per share in a private placement to new and existing investors. DnB NOR Markets acted as manager...

NorwayNorway

03.11.2010

Oslo – The Oslo Cancer Cluster and the Shanghai Institute of Materia Medica (SIMM), have signed a memorandum of understanding aimed at accelerating the development and adoption of new cancer therapies. Overall, the collaboration...

NorwayNorway

18.09.2010

Oslo/Berlin – Algeta is cashing in on its lead product Alpharadin, a targeted alpha-radiopharmaceutical in clinical trials for treating bone metastases in cancer patients. Bayer Schering Pharma has agreed to pay the Norwegian...

NorwayNorway

11.07.2010

Lysaker – Norwegian biopharmaceutical company PCI Biotech Holding ASA has strengthened the company’s equity by a11m (NOK90m) through a share issue of 2.25 million shares with preemptive subscription rights for existing...

Displaying results 11 to 20 out of 92

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-norway/browse/1/article/norway-biobank-assets-to-be-privatised.html

Product of the week

Products

Events

All Events

Current issue

All issues